Statement KOBAYASHI Pharmaceutical (Singapore) Pte. Ltd in order to assist Kobayashi Pharmaceutical Co., Ltd. voluntarily recalling products related to the use of "Beni-koji" ingredient.

KOBAYASHI Pharmaceutical Co., Ltd. (Head office: Osaka, Japan; President: Akihiro Kobayashi) has received a report that kidney problems have occurred in those who consumed "Beni-koji Cholestehelp", a foods with functional claims marketed by us. In response, we conducted an ingredient analysis of this product and the “Beni-koji” ingredients used in it (manufactured by us) where we found that some of the “Beni-koji” ingredients may contain components that we did not anticipate.

At this point in time, we have not been able to identify the exact ingredient nor have we been able to clearly identify the causal relationship between this product and experiencing kidney problems. However, as a precautionary measure to prevent the spread of health hazards to our customers, we have decided to voluntarily recall the “Beni-koji” related products listed below as Subject Products. Although KOBAYASHI Pharmaceutical (Singapore) does not sell the products in Singapore, customers who have purchased the product in Japan, etc. may contact KOBAYASHI Pharmaceutical (Singapore) to request collection.

We deeply apologize for any inconvenience this may cause to our customers and other concerned parties. We consider this to be a serious matter and will continue to investigate.

<Request to our Customers>
For customers who have any of the Subject Products listed, we ask that you please discontinue the use of the product and refrain from consuming it in the future. In addition, for customers who have consumed the Subject Products and feel any physical discomfort, please contact KOBAYASHI Pharmaceutical (Singapore).

<How to Return>
If you have any of the Subject Products, please contact KOBAYASHI Pharmaceutical (Singapore). We will provide you with information on how to return the products and the method for refunds.

<Contact Information>

Visit the website of KOBAYASHI Pharmaceutical (Singapore), click on the "Contact us" at the top of the page to submit your inquiry.

<Subject Products>
According to the announcement from Kobayashi Pharmaceutical Co., Ltd., this voluntary recall involves the following three products:

Thank you very much for your understanding and support.

KOBAYASHI Pharmaceutical (Singapore)
March 29th, 2024